Clinical Trial Update: Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/IIa trial evaluating cabazitaxel plus bavituximab in castration-resistant prostate cancer was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• Jevtana (cabazitaxel)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-07-13